Mary E. Godwin Sells 35,000 Shares of Nautilus Biotechnology, Inc. (NASDAQ:NAUT) Stock

Nautilus Biotechnology, Inc. (NASDAQ:NAUT) VP Mary E. Godwin sold 35,000 shares of Nautilus Biotechnology stock in a transaction dated Tuesday, September 17th. The shares were sold at an average price of $2.85, for a total value of $99,750.00. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website.

Nautilus Biotechnology Price Performance

NASDAQ NAUT opened at $3.00 on Friday. Nautilus Biotechnology, Inc. has a 1-year low of $2.19 and a 1-year high of $3.62. The firm has a market capitalization of $375.80 million, a P/E ratio of -5.45 and a beta of 1.20. The business’s 50-day simple moving average is $2.58 and its 200-day simple moving average is $2.59.

Nautilus Biotechnology (NASDAQ:NAUT) last announced its quarterly earnings results on Tuesday, July 30th. The company reported ($0.14) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.16) by $0.02. During the same quarter last year, the firm earned ($0.13) EPS. On average, equities research analysts expect that Nautilus Biotechnology, Inc. will post -0.65 EPS for the current fiscal year.

Hedge Funds Weigh In On Nautilus Biotechnology

Several hedge funds and other institutional investors have recently made changes to their positions in the business. Renaissance Technologies LLC raised its position in Nautilus Biotechnology by 11.2% in the second quarter. Renaissance Technologies LLC now owns 140,100 shares of the company’s stock valued at $328,000 after purchasing an additional 14,100 shares during the period. Dimensional Fund Advisors LP grew its stake in shares of Nautilus Biotechnology by 19.8% in the second quarter. Dimensional Fund Advisors LP now owns 574,844 shares of the company’s stock valued at $1,345,000 after buying an additional 94,908 shares in the last quarter. Clarius Group LLC raised its holdings in shares of Nautilus Biotechnology by 2.7% during the 2nd quarter. Clarius Group LLC now owns 636,532 shares of the company’s stock valued at $1,489,000 after buying an additional 16,661 shares during the period. Price T Rowe Associates Inc. MD lifted its position in Nautilus Biotechnology by 35.8% during the 1st quarter. Price T Rowe Associates Inc. MD now owns 16,078 shares of the company’s stock worth $48,000 after acquiring an additional 4,239 shares in the last quarter. Finally, Vanguard Group Inc. boosted its holdings in Nautilus Biotechnology by 1.0% in the 1st quarter. Vanguard Group Inc. now owns 2,859,402 shares of the company’s stock worth $8,407,000 after acquiring an additional 29,604 shares during the period. Institutional investors and hedge funds own 50.71% of the company’s stock.

Analyst Upgrades and Downgrades

NAUT has been the subject of a number of recent analyst reports. Jefferies Financial Group initiated coverage on shares of Nautilus Biotechnology in a report on Monday, June 3rd. They issued a “hold” rating and a $3.00 target price for the company. Guggenheim started coverage on shares of Nautilus Biotechnology in a research note on Thursday, June 27th. They set a “buy” rating and a $6.00 price objective for the company.

About Nautilus Biotechnology

Nautilus Biotechnology, Inc, a development stage life sciences company, engages in creating a platform technology for quantifying and unlocking the complexity of the proteome. The company develops Nautilus Platform, a proteomics platform that includes end-to-end solution comprised of instruments, consumables, and software analysis.